235 related articles for article (PubMed ID: 18713495)
1. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Sun F; Chen Y; Xiang Y; Zhan S
Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
Cai Y; Yi J; Zhou C; Shen X
PLoS One; 2012; 7(10):e47769. PubMed ID: 23082213
[TBL] [Abstract][Full Text] [Related]
3. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphisms of
Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
[TBL] [Abstract][Full Text] [Related]
5. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
6.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Vasquez-Dominguez A; Toledo-Nauto A; Capristano S; Sanchez C; Tarazona-Santos E; Ugarte-Gil C; Guio H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232322
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.
Feng FM; Guo M; Chen Y; Li SM; Zhang P; Sun SF; Zhang GS
Genet Mol Res; 2014 Nov; 13(4):9463-71. PubMed ID: 25501156
[TBL] [Abstract][Full Text] [Related]
8. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy.
Forestiero FJ; Cecon L; Hirata MH; de Melo FF; Cardoso RF; Cerda A; Hirata RD
Clin Chim Acta; 2013 Jan; 415():215-9. PubMed ID: 23099118
[TBL] [Abstract][Full Text] [Related]
9. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
Tang SW; Lv XZ; Zhang Y; Wu SS; Yang ZR; Xia YY; Tu DH; Deng PY; Ma Y; Chen DF; Zhan SY
J Clin Pharm Ther; 2012 Oct; 37(5):588-93. PubMed ID: 22335459
[TBL] [Abstract][Full Text] [Related]
10. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.
Rana SV; Sharma SK; Ola RP; Kamboj JK; Malik A; Morya RK; Sinha SK
J Clin Pharm Ther; 2014 Feb; 39(1):91-6. PubMed ID: 24188272
[TBL] [Abstract][Full Text] [Related]
11. Are genetic variations in glutathione S-transferases involved in anti-tuberculosis drug-induced liver injury? A meta-analysis.
Zhang M; Wu SQ; He JQ
J Clin Pharm Ther; 2019 Dec; 44(6):844-857. PubMed ID: 31378997
[TBL] [Abstract][Full Text] [Related]
12. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
14. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
15. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients.
Zhang D; Hao J; Hou R; Yu Y; Hu B; Wei L
J Clin Pharm Ther; 2020 Jun; 45(3):561-569. PubMed ID: 32364660
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation.
Roy B; Chowdhury A; Kundu S; Santra A; Dey B; Chakraborty M; Majumder PP
J Gastroenterol Hepatol; 2001 Sep; 16(9):1033-7. PubMed ID: 11595069
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.
Huang YS
J Chin Med Assoc; 2014 Apr; 77(4):169-73. PubMed ID: 24593909
[TBL] [Abstract][Full Text] [Related]
19. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
20. Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST.
Santos EA; Gonçalves JCS; Fleury MK; Kritski AL; Oliveira MM; Velasque LS; E Silva JRL; Estrela RCE
Braz J Infect Dis; 2019; 23(6):381-387. PubMed ID: 31697922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
